中航高科(600862.SH):優材百慕擬增資擴股 公司放棄優先認購權
格隆匯5月28日丨中航高科(600862.SH)公佈,公司控股子公司北京優材百慕航空器材有限公司(以下簡稱“優材百慕”)擬通過公開掛牌方式引進不超過4家產業投資者和1家財務投資者進行增資,融資規模不超過2.17億元。
綜合考慮優材百慕混合所有制改革整體規劃、經營發展情況及經營現狀後,公司不參加本次增資並放棄優先認購權。持有優材百慕18.256%股份的北京優材眾智新材料有限合夥(有限合夥)已放棄優先認購權。
增資擴股完成後,公司持有優材百慕股權比例預計不低於45%,能夠通過董事會對其實施控制,因此,優材百慕仍在公司合併報表範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.